Objective: To test if sequence variations of the SYNTAXIN 1A (STX1A) gene contribute to the susceptibility to type 2 diabetes in a cohort of overweight/obese subjects. Methods: A total of 717 overweight/obese individuals underwent oral glucose tolerance test and were stratified in four groups according to fasting and 2 h glucose levels (NGT, IGT, CGI, T2DM), representing the natural history of diabetes from normal glucose tolerance to overt disease. These subjects were analysed by a two-step genetic study. Functional analysis was performed by electrophoretic mobility shift assay (EMSA) and by supershift with CCAAT/enhancer-binding protein (C/EBP)b antibody. Results: Among the several sequence variations detected in the STX1A gene, the T allele of the À352 A4T single nucleotide polymorphism in the promoter was found in a lower frequency in the subset of individuals with greater impairment of insulin secretion (CGI). To confirm that a lower frequency of the T allele was associated with this condition, we genotyped a second group of 202 overweight/obese individuals with type 2 diabetes, and the frequency of the T allele was reduced in this group also (Po0.01). Logistic regression confirmed a protective odds ratio (0.49, Po0.01) for the T allele. The EMSA showed that the PRM À352 A allele binds transcription factors with lower affinity compared to the T allele, and incubation with C/EBPb antibody 'supershifted' the complex, indicating that C/EBPb had a different binding with the PRM À352T allele. Conclusion: A lower frequency of the PRM À352T allele of the STX1A gene was observed in overweight/obese subjects with impaired glucose regulation, particularly among individuals with combined glucose intolerance and overt diabetes. Both these groups have a greater defect in b-cell function compared to normal and glucose intolerant subjects, and this association together with the functional study suggests a possible role of the PRM À352 A4T variant in insulin secretion.
Introduction
Obesity is a well-established risk factor in the pathogenesis of type 2 diabetes mellitus (T2DM). The excess and the visceral localization of body fat contribute to generate resistance to physiological insulin action. In the natural history of type 2 diabetes, elevated plasma glucose appears when pancreatic b-cells fail to provide adequate amounts of insulin to compensate for the increasing insulin resistance. The UK Prospective Diabetes Study Group data clearly show that patients, at the time of diagnosis of type 2 diabetes, have already a 50% reduction in pancreatic b-cell function with concomitant insulin resistance, and that, over time, there is an estimated 4% loss in b-cell function per year regardless of treatment. 1 Thus, genetic susceptibility to defective insulin secretion, as well as for insulin resistance, is considered one of the key factors responsible for the disease. 2 Insulin exocytosis depends on the intracellular storing of insulin within vesicles, vesicle trafficking and fusion to the membrane of pancreatic b-cells.
3,4 SNARE proteins (soluble N-ethylmaleimide-sensitive factor attachment protein receptors), a calcium-dependent family of proteins first discovered in the neuronal tissue, participate in the complex regulation of insulin secretion. SNARE proteins constitute the 'core complex' that regulates vesicle trafficking and fusion in b-cells. 5 Within these proteins, Syntaxin 1A (STX1A) has been shown to bind and regulate calcium channels and voltagegated K þ channels of the pancreatic b-cell. 6, 7 STX1A expression is severely reduced in GK rats, an animal model of T2DM, and this reduction is associated with impaired insulin secretion. 8 Recently, in transgenic mice for STX1A, it was demonstrated that subtle fluctuations in the expression of this protein determined changes in insulin secretion, also causing glucose intolerance in these animals. 9 The STX1A gene has been mapped to chromosome 7q11. Earlier studies have linked to 7q a 'diabesity' locus in the Pima Indians 10 and an obesity region in Mexican
Americans. 11 Very recently, a quantitative trait locus for fasting glucose has been found linked to 7q in Europeans, 12 thus adding confirmatory evidence that this region may contain gene or genes with important impact on regulating insulin and glucose metabolism. 13 Previously, Tsunoda et al. 14 reported that the rs2293485 single nucleotide polymorphism (SNP) of the STX1A gene was associated with earlier age of onset and higher daily insulin requirement in individuals with type 2 diabetes of Asian descent. These evidences support the STX1A gene as a possible candidate gene in the genetic susceptibility to defective insulin production. The aim of this study was to test if STX1A gene sequence variations contribute to the risk of diabetes in obese and overweight Caucasian subjects from Italy. Since the progressive impairment of insulin secretion is necessary to the complete onset of type 2 diabetes, 1 we first studied this gene in a sample of subjects at higher risk for diabetes, to test the hypothesis that variants of the STX1A gene may contribute to the susceptibility to pancreatic b-cell impairment. Next, we investigated the STX1A gene variants in a group of overweight/obese subjects with type 2 diabetes, and finally we performed a functional study to understand the possible mechanisms underlying the genetic association.
Methods

Subjects
A total of 717 overweight/obese subjects (inclusion criterion was body mass index 425 kg m À2 ) were studied. All unrelated Caucasian subjects were recruited from subjects referred to our department for diabetes risk evaluation, and they were all living in the centre-west region of Italy. All subjects underwent complete medical history, physical examination, routine laboratory tests, ECG and standard oral glucose tolerance test (OGTT).
After the OGTT, the subjects were classified as NGT (normal glucose tolerant) (n ¼ 262), IGT (impaired glucose tolerant) (n ¼ 150), CGI (combined glucose impairment, including both impaired glucose tolerance and impaired fasting glucose) (n ¼ 103) and T2DM. NGT, IFG, IGT and T2DM were defined according to the American Diabetes Association (ADA) 2003 diagnostic criteria. Individuals were defined as CGI if fasting glucose was 5.5-6.9 mmol l À1 and 2 h glucose between 7.7 and 10.9 mmol l À1 . All subjects with T2DM were newly diagnosed and therefore were not taking any blood glucose-lowering treatment at the time of the study. This way, any pharmacological interference on parameters of insulin secretion and action was avoided. Exclusion criteria were the presence of endocrine, liver or kidney diseases. Also, hypertensive patients treated with b-blockers or diuretics, which could interfere with glucose regulation, were excluded. The clinical characteristics of all subjects included in the study are shown in Table 1 . Table 1 Clinical and laboratory characteristics of the subjects studied in individuals stratified according to fasting and 2 h glucose after oral administration of 75 g of glucose We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research. This study was approved by the university review committee and informed consent was obtained from all the subjects participating in the study.
Biological measurements
Plasma glucose was determined by the glucose oxidase method (Glucose Autoanalyzer, Beckman Coulter Inc., Fullerton, CA, USA; coefficient of variation, 1.970.2%). Plasma insulin concentration was measured on frozen samples using a radio immunoassay (Biodata Insulin Kit, Milan, Italy) with an interassay coefficient of variation of 7.5%. Cholesterol and triglyceride concentrations in total plasma were measured with a Technicon RA-1000 Autoanalyzer. High-density lipoprotein cholesterol was determined in the whole plasma after precipitation of apoB-containing lipoproteins with phosphotungstic acid/MgCl 2 .
The OGTT was performed after a 10-h overnight fast: subjects ingested a solution containing 75 g dextrose, and venous blood samples were obtained after 0 and 120 min to measure serum glucose and serum insulin. Screening for DNA sequence variations DNA was obtained from white blood cell extraction by salting-out method. STX1A gene maps to chromosome 7q11.2, 16 and the coding sequence includes 10 exons and a promoter (from nucleotide À571). A total of 120 randomly selected obese individuals divided in three numerically equal groups (NGT, IGT and CGI) underwent genetic screening to identify common variants in the STX1A gene. All exons including intron-exon boundaries and the 3 0 -UTR region were amplified by standard PCR. Primers for all exons were synthesized according to previous methods.
Indices of insulin secretion and insulin resistance
14 Primers for the 3 0 -UTR and promoter regions were newly designed with reference to the STX1A genomic DNA sequence (chromosome 7, Genomic Position: 72751476-72771898, UCSC Genome Bioinformatics Site (human version 2006)). PCR fragments were screened for mutation by mutation detection enhancement-single strand conformation polymorphism (MDE-SSCP) followed by silver staining as described previously. 17 In our lab, this method has 90-95% sensitivity for mutation detection. To ensure long-term reproducibility of the method in each experiment, two control samples carrying the À352 A4T variant (AT and TT genotype) were run on the gel. Variants detected with MDE-SSCP were then sequenced with ABI prism 310 according to the manufacturer's instructions. Genotyping success rate was 490% for all SNPs. Genotype duplicates concordance evaluation was performed by random (10% of the total screened) regenotyping and resulted in 100%. The SNP in exon 3 D68D T4C was analysed by PCR-RFPL with Hpy 99-I enzyme according to Wong et al. 18 The À352
A/T variant was screened in all subjects by MDE-SSCP and sequencing since no restriction enzyme was available.
Electrophoretic mobility shift assay and supershift assay Electrophoretic mobility shift assay (EMSA) was performed on the PRM À352 A4T polymorphism of the STX1A gene. Human insulinoma cell line (CM) was cultured as described previously 19, 20 and nuclear proteins were extracted according to the method described by Dignam et al. 21 Semiquantitative reverse transcriptase-PCR was used to quantify the expression of the STX1A gene. TRIzol reagent (Gibco BRL, Milan, Italy) was used for RNA extraction and Superscript reverse transcriptase system (Gibco BRL) was used for retrotranscription. The cDNA obtained was further amplified by PCR with specific oligonucleotides. Two double-stranded 30-mer oligonucleotides corresponding to the A or T allele were radiolabeled using [g-32 P]ATP and T4 polynucleotide kinase using standard procedures. Binding reaction was carried out with or without competitor on 2 ml of nuclear extract at room temperature for 30 min in a total volume of 40 ml. Bound complexes were then separated on a 5% non-denaturing polyacrylamide gel by electrophoresis in 0.5 Â TBE buffer, dried and visualized by autoradiography. Supershift was performed by pre-incubating the binding reaction mixture with rabbit polyclonal antibody to CCAAT/ enhancer-binding protein (C/EBP)b recommended for detection of C/EBPb, C/EBPa and C/EBPd (Santa Cruz, Heidelberg, Germany). Gel electrophoresis was run as above. To estimate the risk of CGI/T2DM associated with the sequence variation found in the promoter region of STX1A gene, odds ratios (ORs) were calculated by multivariate logistic regression analysis using age, sex and body mass index as covariates. P-values o0.05 were taken as statistically significant. For genetic analysis, nominal P-values were considered if o0.05. Bonferroni's correction was applied when multiple sequence variations were tested. In particular, in the first genetic screening, we compared the allele distributions of the five sequence variations with a minor allele frequency 40.01 in NGT vs CGI subjects, and the P-values were corrected by 5 ( Table 2 ). In step two, the P-values were corrected by 2 (analysis of the rs2293485 and PRM À352A/T sequence variations; Table 4 ).
Statistical analysis
Computer softwares
The softwares TESS MASTER (Transcription Element Search Software, http://www.cbil.upenn.edu.tess) and TFSEARCH (TFSEARCH: Searching Transcription Factor Binding Sites, http://www.rwcp.or.jp/papia/) were used to predict promoter-binding factor sequences located close to À352 A4T polymorphism. Statistical analyses were performed with SPSS 14.0 statistical package. The EMSA was quantified using the ImageJ 1.37 program (available at http://rsb.info.nih.gov/ij/).
Results
Population characteristics
The clinical characteristics of the study subjects are shown in Table 1 . A total of 717 individuals were referred to our department for the presence of obesity and they all underwent OGTT. According to their fasting and 2 h plasma glucose levels, the subjects were then stratified in four subsets: (1) NGT (n ¼ 262); (2) IGT (n ¼ 150); (3) CGI (n ¼ 103), which includes those with both IGT and IFG, and subjects with T2DM (n ¼ 202) (Table 1) .
Compared to NGT, IGT subjects showed a significantly higher insulin resistance (median HOMA-IR: 4.8 vs 3.4, Po0.001) with no differences in b-cell function (HOMA-B%: 104 vs 100). The CGI group showed a greater insulin resistance (HOMA-IR: 7.7 vs 3.4, Po0.001) and a lower b-cell function (HOMA-B%: 68 vs 100, Po0.001) compared to NGT. Also IGT and CGI subjects had two common features related to obesity: a greater systolic (P ¼ 0.037) and diastolic blood pressure (P ¼ 0.012) and higher levels of triglycerides compared to NGT. Finally, IGT subjects showed significantly lower basal insulin, greater insulin secretion index (HOMA-B%) and a significantly higher sensitivity to insulin (lower HOMA-IR) compared to CGI subjects (all P-values o0.01).
The subjects with diabetes (T2DM), although overweight, had a lower body mass index (Po0.001) compared to the NGT, IGT and CGI groups (Po0.01) together with a reduction of 50% of b-cell function compared to the NGT and IGT subjects (HOMA-B% index Po0.001). The T2DM subjects also showed greater systolic blood pressure compared to NGT (Po0.001), but no difference in diastolic blood pressure, possibly because of the higher frequency of subjects treated with blood pressure-lowering drugs in the diabetic group.
Genetic association study
To reduce the occurrence of false positive in our results, we designed a two-step genetic association study. The hypothesis of our study was that sequence variations of STX1A may have a different distribution in our population, stratified by the differences in glucose regulation.
Step 1 consisted in an initial screening of 120 randomly selected obese individuals divided in three numerically equal groups (NGT, IGT and CGI), aimed to identify common variants in the STX1A gene, followed by the analysis of the distribution of the sequence variants among the three groups. Two sequence variations (the PRM À352 A4T and the rs2293485 SNPs) were selected on the basis of the different distribution among the NGT, IGT and CGI groups and/or because of previously published evidence of association, and were genotyped in a total of 515 obese individuals. In step 2, we genotyped the subset of individuals with diabetes mellitus to confirm the hypothesis that specific sequence variations were associated with impaired glucose regulation. SYNTAXIN 1A gene and glucose metabolism S Romeo et al
Step 1: screening for sequence variations and genotyping of the PRM À352 A4T SNP in 515 non-diabetic obese subjects A total of eight sequence variations were found across the STX1A gene ( Figure 1 ): one in the promoter region 352 bp upstream of the ATG codon (PRM À352 A4T), a synonymous variant in exon 3 (D68D T4C, rs2293485), three SNPs in the 3 0 -UTR region and three in the introns. The sequence variations found in the 3 0 -UTR were rare variants (minor allele frequency o0.01).
Allele frequencies of the variants were not different among the obese subjects stratified in NGT, IGT and CGI groups, except for the PRM À352 A4T (Table 2 ). In the PRM À352 A4T SNP, we found a reduction of the T allele frequencies in the CGI group (0.12) compared to NGT and IGT (0.36 and 0.34, respectively, Pearson's w 2 , 2 d.f., Po0.05, after Bonferroni's correction).
To verify the reduction of the T allele for the PRM À352 A4T SNP in the CGI group, we genotyped this sequence variation in a total of 515 obese individuals crossing all the spectrum of glucose regulation preceding diabetes onset (NGT ¼ 262, IGT ¼ 150, CGI ¼ 103). Genotype frequencies for the PRM À352 A4T SNP were AA (0.66), AT (0.32) and TT (0.02) and were in Hardy-Weinberg equilibrium.
The frequencies for the PRM À352T allele were not different between NGT and IGT subjects (Table 3) , but there was a significant reduction in the frequency of T allele carriers in the CGI group compared to the other groups (0.13 vs 0.22 and 0.20, Po0.05 after Bonferroni's correction; Table 3 ). This group with combined glucose intolerance is a subset of individuals with a greater impairment in glucose regulation, due both to a significantly lower insulin secretion and a higher insulin resistance compared to IGT and NGT (Table 1) .
Step 2: genotyping of the PRM À352 A4T in 202 overweight/ obese subjects with diabetes mellitus To confirm the association with a lower prevalence of the PRM À352 T allele in the subset of individuals with an established defect in glucose metabolism, we genotyped this sequence variation in a group of 202 individuals with diabetes mellitus, predicting a lower frequency of the T allele in this group compared to the NGT and IGT groups.
The frequency of the PRM À352T allele was significantly different between NGT and T2DM subjects, with a lower frequency of the T allele in the latter group (0.22 in NGT and 0.13 in T2DM, Po0.01). When IGT and CGI subjects were compared to T2DM subjects, the frequency of the T allele was statistically different only between IGT and T2DM subjects (0.20 in IGT and 0.13 in T2DM, Po0.05 after Bonferroni's correction). Allele frequencies in CGI subjects were not different from T2DM patients. We thus compared allele frequencies of the PRM À352 A4T SNP between NGT þ IGT and CG1 þ T2DM, that is subjects with and without insulin secretion defects. This analysis confirmed that in CGI þ T2DM subjects, the frequency of the T allele (0.13) was significantly lower than in NGT þ IGT (0.22) (Po0.001 after Bonferroni's correction) ( Table 4) .
When clinical and metabolic parameters were compared between carriers and non-carriers in the whole population, T allele carriers showed lower fasting blood glucose compared to non-carriers (mean 91728 vs 104733 mmol l À1 , Po0.05).
Furthermore, HOMA-B% was significantly lower (Po0.05) in AA carriers (median 74% (52-138) vs 90% (41-122)). All 
To further assess if the PRM À352 A4T SNP is independently associated with diabetes/CGI status, taken together as the categories with the worst glucose regulation, we performed multivariate analysis to control for the effect of other modulators known to be independently associated with these conditions. We entered in the logistic model sex, age, body mass index and the allele status for the PRM À352 A4T SNP. Logistic regression analysis in the whole population showed that sex (OR, 4.2; confidence interval: 2.6-6.8; Po0.001), age (OR: 1.09; confidence interval: 1.07-1.11; Po0.001) and carrier status at the PRM À352 A4T SNP (OR: 0.49; confidence interval: 0.30-0.81; P ¼ 0.005) were significantly and independently associated to the diabetes/CGI status.
Genotyping of the rs2293485 in the entire population Since the rs2293485 SNP has been previously found associated with type 2 diabetes in subjects of Asian descent, 14 we also analysed this sequence variation in our population of 717 individuals. Genotype frequencies for the rs2293485 SNP were TT (23%), CT (51%) and CC (26%) in HardyWeinberg equilibrium. Both dominant and recessive models were used to test the distribution of this SNP among groups. Genotype and allele frequencies of the rs2293485 SNP were not statistically different among NGT, IGT, CGI and T2DM subjects (data not shown). Also, there was no difference in the genotype and allele frequencies when cases (T2DM þ CGI ¼ 305) were compared to controls (IGT þ NGT ¼ 412) (Table 4) .
Electrophoretic mobility shift
Small fluctuations in the expression of STX1A were shown to determine changes in glucose regulation through the impairment of insulin secretion in transgenic mice. 9 To test the hypothesis that the PRM À352 A4T sequence variation is responsible for altered binding of nuclear factors in pancreatic b-cells, we performed an in vitro EMSA on the human insulinoma CM cell line, which has been shown in several studies to be very similar to human pancreatic b-cells. 19, 20 Prior to the EMSA, using reverse transcriptase-PCR, we confirmed the expression of the STX1A gene in the human insulinoma (CM) cells (Figure 2a) . Two double-stranded 30-mer oligonucleotide probes corresponding to the A and T allele were generated from the promoter region. The PRM À352 A or T probes formed a DNA-protein complex with nuclear extracts from the CM insulinoma cell line, and binding was efficiently competed by an excess of unlabeled probe (Figure 2b ). Interestingly, in the EMSA experiments, the complexes formed with the T probes were consistently more intense (an average E20% increase, Po0.05; Figure 2b ) than the A probes. Identical allele-dependent differences in binding were observed on repeating EMSA for five times, suggesting that the PRM À352 A4T SNP does affect nuclear protein(s) binding and that the A allele has a lower affinity for binding compared with the T allele.
The search (with TESS and TFSEARCH softwares) for potential transcription factor-binding sequences within position PRM À352 revealed a C/EBP-binding sequence. The analysis also revealed that the matrix match score of PRM À352T variant was slightly higher than that of the PRM À352A variant (92 vs 88%), indicating that C/EBP has a higher affinity to the À352T variant than to the À352 A variant. As this correlates to our gel shift results, we decided to further characterize the protein/DNA interactions in the PRM À352 region by adding an anti-C/EBPb antibody. Addition of the C/EBPb antibody resulted in a 'supershifted' migration of the complex (Figure 2c ).
Discussion
The present study provides evidence of association between the PRM À352T allele of the STX1A gene and protection from impaired glucose regulation in a cohort of overweight/obese subjects undergoing a screening for diabetes mellitus. Excess in body weight is probably the most important environmental risk factor for T2DM. We tested the hypothesis that sequence variations in the STX1A gene may contribute to the susceptibility to type 2 diabetes specifically in a high-risk group of overweight and obese individuals. As false positive associations are common in genetic studies, to reduce this occurrence, we designed a two-step case-control study.
Initially, we screened the STX1A gene for sequence variations in 40 randomly selected NGT subjects, 40 individuals with IGT and 40 individuals with combined 14,18 STX1A gene resulted in eight nucleotide variations with no evidence of nonsynonymous sequence variations. The variants identified in the 3 0 -UTR region were rare. On the basis of the genotype frequencies among the three groups in the initial genetic screening, we genotyped the PRM À352 A4T and the rs2293485 SNPs in a total of 515 obese subjects stratified by glucose tolerance (NGT, IGT and CGI). We found that the T allele frequency in the À352 A4T SNP was significantly lower in CGI subjects, the group with the greater impairment in glucose regulation. These subjects, compared to IGT, have a greater reduction in their pancreatic b-cell function, representing an intermediate state preceding the onset of diabetes. 22 To confirm the hypothesis that the frequency of the T allele was lower in a group with impaired insulin secretion, we genotyped the group of overweight and obese subjects with T2DM, which have a definite altered insulin secretion. In this group, we observed the T allele at a frequency same as that in the CGI group (0.13), with a reduction of 41% compared to the NGT (0.22) and the IGT (0.20) groups (Po0.01). Finally, to quantify the protection on impaired glucose regulation in À352T allele carriers and to correct for other diabetes risk factors, we performed multivariate logistic regression analysis that showed a significant and independent reduction in the risk of the CGI/T2DM onset OR (0.49, Po0.01).
In transgenic mice, it was shown that subtle fluctuations in the expression of STX1A are associated with perturbations in glucose regulation through impaired insulin secretion. 9 Although non-synonymous sequence variations are more likely to affect protein function, nucleotide sequence variation in the promoter region may have functional effects as well. To investigate the possible functional role of the PRM À352 A4T polymorphism, we therefore performed an EMSA to test for differences in nuclear protein binding to the STX1A promoter in human insulinoma cells. The results from the EMSA study showed that the PRM À352 A4T polymorphic site is involved in the specific binding to a nuclear protein. Moreover, there was an allele-dependent binding to a putative transcriptional factor, with the PRM À352 A allele binding with lower affinity than the T allele (Figure 2b) . In silico analysis revealed a C/EBP-binding sequence within position PRM À352, and addition of the C/EBPb antibody resulted in a supershift of the complex. C/EBP transcription factors belong to a basic region-leucine zipper (bZIP) family of transcription factors expressed in several organs. 23 Specifically in the pancreatic b-cells, C/EBPb has been shown to modulate the transcription of the insulin gene, 24 with an inhibitory effect on insulin secretion. In our EMSA experiments, we observed a different binding between T or A probes and protein extracts, and the presence of the C/EBPb antibody resulted in a supershift of the complex. In view of these observations, our data suggest a possible involvement of the PRM À352 A4T SNP in b-cell function.
With regard to the rs2293485 SNP, there was no difference in the genotype frequency in the three groups (NGT, IGT, CGI). This SNP was previously associated with type 2 diabetes in a case-control study of subjects of Asian descent, 14 but the results of this study did not support this association. In summary, we have observed a lower frequency of the PRM À352T allele of the STX1A gene in obese subjects with impaired glucose regulation, particularly among individuals with combined glucose intolerance and overt diabetes. Both these groups have a greater defect in b-cell function compared to the normal and glucose intolerant obese subjects. The protection conferred by the PRM À352T allele may be explained by the different binding to the nuclear C/EBPb transcription factors. Further studies are warranted to confirm our results and to elucidate the molecular mechanisms of the observed association.
